Intraoral grafting of an ex vivo produced oral mucosa equivalent: a

Transcription

Intraoral grafting of an ex vivo produced oral mucosa equivalent: a
Int. J. Oral Maxillofac. Surg. 2003; 32: 188–197
doi:10.1054/ijom.2002.0365, available online at http://www.sciencedirect.com
Research paper
Tissue Engineering
Intraoral grafting of an ex vivo
produced oral mucosa
equivalent: a preliminary report
K. Izumi1,2, S. E. Feinberg2, A. Iida1,
M. Yoshizawa1
1
Department of Oral and Maxillofacial Surgery,
Course for Oral Life Science, Niigata
University Postgraduate School of Medical
and Dental Sciences, Japan; 2Department of
Oral and Maxillofacial Surgery, University of
Michigan Medical Center, Ann Arbor, MI, USA
K. Izumi, S. E. Feinberg, A. Iida, M. Yoshizawa: Intraoral grafting of an ex vivo
produced oral mucosa equivalent: a preliminary report. Int. J. Oral Maxillofac. Surg.
2003; 32: 188–197. 2003 International Association of Oral and Maxillofacial
Surgeons. Published by Elsevier Science Ltd. All rights reserved.
Abstract. The objective of this study was to assess the efficacy of the use of an
ex vivo produced oral mucosa equivalent (EVPOME) for intraoral grafting
procedures. Autogenous keratinocytes were harvested from a punch biopsy 4 weeks
prior to surgery, placed in a serum-free culture system and seeded onto a human
cadaveric dermal equivalent, AlloDerm. Thirty patients with either a
premalignant or cancerous lesion were triaged into two groups, depending on the
stage of disease: Group 1: EVPOME or Group 2: AlloDerm, control without an
epithelial layer. Clinically, EVPOME grafts were easy to handle and showed
excellent compliance on grafting. Both, EVPOME and AlloDerm grafts, showed
a 100% take rate. At 6 days post-grafting, the EVPOME clinically showed changes
indicating vascular ingrowth and had cytologic evidence of the persistence of
grafted cultured keratinocytes on the surface. The EVPOME grafts had enhanced
maturation of the underlying submucosal layer associated with rapid epithelial
coverage when compared to the AlloDerm grafts at biopsies taken at 28 days
post-grafting. In summary, EVPOME appears to be an acceptable oral mucosal
substitute for human intraoral grafting procedures and results in a more favorable
wound healing response than AlloDerm alone.
Introduction
Preprosthetic and reconstructive procedures often result in open wounds in
the mouth during intraoral surgery. A
free mucosal graft used for reconstruction or closure of the open wounds can
prevent microbial infection, excessive
fluid loss, and foreign material contamination or relapse secondary to wound
contracture. Oral mucosa or skin grafts
both require harvesting of tissue from a
second surgical site resulting in increase
patient morbidity. In addition, oral
mucosa is limited in supply while splitthickness skin grafts, though more easily
0901-5027/03/020188+10 $30.00/0
available, contain adnexal structures,
and express a different pattern of keratinization9. Technological advancements
in the field of tissue-engineering have
allowed the development of innovative
approaches to the fabrication of skin
and mucosal substitutes17. Over the last
decade, two prevalent skin substitute
methods have been frequently used in
oral and maxillofacial surgery. One is a
mucosal epithelial sheet fabricated by
the technique developed by G and
R4. However, several disadvantages of the use of sheets of epithelial cells exist. First is the difficulty in
handling of the friable epithelial sheets.
Key words: tissue-engineering; oral mucosa
equivalent; AlloDerm®; oral keratinocytes;
human clinical trial.
Accepted for publication 17 December 2002
Second is the use of an irradiated xenogeneic 3T3 mouse fibroblast feeder layer
that is necessary to enhance growth of
cultured keratinocytes. Unfortunately,
the feeder layer has the potential to
transfer xenogenous components to the
co-cultured autologous cells of the
grafted patients4,18,19. A second skin
substitute technique uses a bi-layered
artificial dermis that consists of collagenglycosaminoglycan/silastic sheet1,14 that
is an ‘off-the-shelf’ material that is
available at the time of surgery. Its
major shortcomings are its difficulty
with suturing and its susceptibility to
infection17.
2003 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Science Ltd. All rights reserved.
Intraoral grafting of an ex vivo produced oral mucosa equivalent
189
reconstruction. To our knowledge, this
is the first reported clinical study using
a tissue-engineered ex vivo produced
human oral mucosa composed of both
an epithelial and dermal component for
intraoral grafting procedures with an
experimental protocol that includes a
parallel control group, AlloDerm,
without epithelium.
Experimental design and
methodology
Fabrication of Ex vivo Produced Oral
Mucosa Equivalent (EVPOME)
Fig. 1. A. Photomicrograph of day 11 EVPOME illustrating epithelial cell stratification with
evidence of parakeratinization (haematoxylin and eosin staining, original magnification
(250). B. EVPOME illustrating its tensile strength.
Our research team has been able to
overcome these disadvantages by the
development of a human ex vivo
produced oral mucosa equivalent
(EVPOME) in a serum-free culture system without a feeder layer that has excellent handling characteristis9. Our
EVPOME is composed of a stratified
layer of human autogeneous oral keratinocytes seeded on top of an acellular,
human cadaver dermis, AlloDerm. It is
the use of AlloDerm as the dermal
base that confers enhanced handling
characteristics and assists in compliance
of the graft.
The elective nature of maxillofacial
surgical procedures allows the flexibility
and timing to coordinate the manufacture of a human ex vivo produced
engineered-tissue of adequate dimensions within sufficient time to allow its
use in the reconstruction of mucosal
tissues within the oral cavity.
The objective of this study was
to evaluate the efficacy and clinical
handling of EVPOME for intraoral
The development and characteristics
of EVPOME have been previously
described9. EVPOME is a composite
human oral mucosa equivalent consisting of a dermal component composed of
a human cadaver dermis, AlloDerm
(LifeCell, Branchburg, NJ, USA) that is
seeded with autogenous human oral
keratinocytes to form an overlying
stratified
parakeratinized
epithelial
layer. Briefly, our protocol for the manufacture of the EVPOME is the following.
First, in the out patient clinic, under
local anaesthesia, a 55 mm punch
biopsy of keratinized oral mucosa is
taken from an uninvolved site in the oral
cavity. The biopsy is taken at a time
point prior to surgery to allow fabrication of an EVPOME that has appropriate dimensions for the planned surgical
reconstruction. Oral keratinocytes are
dissociated from the biopsy specimen
and expanded in a serum-free defined
culture medium, MCDB153 (Sigma, St
Louis, MO, USA) containing a calcium
concentration of 0.06 mM and porcine
pituitary extract (COSMO BIO, Tokyo,
Japan). The AlloDerm is pre-soaked
in 5 g/cm2 human type IV collagen
(Becton Dickinson Labware, Bedford,
MA, USA) for 3 h prior to seeding to
enhance adherence of the seeded keratinocytes (1.25105 cells/cm2). Once a
sufficient number of oral keratinocytes
has been harvested, they are seeded
onto the collagen coated AlloDerm
(thickness of 0.007 to 0.020 in). The
composites of oral keratinocytes and
AlloDerm are then cultured, submerged, for 4 days to form a continuous
epithelial monolayer. At this time, the
concentration of calcium in the culture
medium is raised to 1.2 mM to enhance
keratinocyte differentiation. When the
equivalents are raised to an air-liquid
interface to encourage stratification of
the epithelial monolayer, they are cultured for an additional 7 days resulting
190
Izumi et al.
Table 1. Research subjects of the EVPOME (Group 1) and AlloDerm alone (Group 2).
Mean age (range)
Group 1
EVPOME (15 pts)
Group 2
AlloDermalone (15 pts)
64.22.7 (49 to 84)
68.03.0 (41 to 84)
Male/female ratio
5/10
10/5
Tongue (13)*
Alveolar gingiva (5)*
Tongue (11)
Buccal mucosa (1)
Floor of mouth (1)
Alveolar gingiva (1)
Oropharyngeal mucosa(1)
Sq. cell carcinoma (6)
Epithelial dysplasia (8)
Oral lichen planus (1)
Sq. cell carcinoma (11)
Epithelial dysplasia (4)
Non-smoker (8)
Previous smoker (3)†
Current smoker (4)‡
Non-smoker (11)
Current smoker (4)‡
Surface area (cm2) to be covered
12.411.70
11.281.83
Follow-up (range)
5–17 months
4–18 months
Site
Diagnoses
Smoking history
*Several patients had multiple sites thus number of sites is greater than 15.
†Previous history of smoking; presently a non-smoker.
‡One smoker is this group of four was classified as a ‘heavy smoker’ (an index showed 1000 or
higher).
in the formation of a parakeratinized
layer in preparation for intraoral grafting of the EVPOME (Fig. 1A).
This optimal fabrication protocol for
the EVPOME, i.e., the number of days
in culture, was determined by experimental studies that involved the grafting
of different stages of epithelial development of the EVPOME into SCID mice.
Grafted EVPOMEs were then evaluated
for microvessel ingrowth within the
underlying AlloDerm layer, since
re-vascularization is an important factor
in free graft survival8. At this stage of
development the EVPOME possessed
excellent handling characteristics that
allowed it to be easily transferred from
the culture flask to the oral cavity (Fig.
1B). These EVPOME grafts have been
referred to as day 11 grafts, and day 10
to 14 grafts are the ones that were used
in this reported study.
Experimental design
All patients enrolled in the study, at
Niigata University, signed a consent
form in which they agreed to be part of
the investigation to evaluate EVPOMEs
for intraoral grafting procedures. Study
subjects were selected from patients
diagnosed with premalignant lesions or
oral cancer who were to undergo surgical excision of the lesion followed by
reconstruction. Patients were triaged
to Group 1, EVPOMEs, or Group 2,
AlloDerm, control group without an
epithelial layer, depending on the
urgency of surgery, since the EVPOME
required additional time to fabricate.
The use of a control group, AlloDerm
without an epithelial layer, allowed us to
assess the efficacy of the use of a stratified layer of oral epithelial keratinocytes
on the dermal equivalent.
Inclusion and exclusion criteria
Inclusion criteria were: (1) over 18 years
of age and (2) diagnosed as oral squamous cell carcinoma or oral premalignant lesion such as dysplasia or
carcinoma in situ. Exclusion criteria
were: (1) serologically positive for syphilis, HIV or Hepatitis B or C virus, (2)
uncontrolled diseases such as diabetes,
pregnancy, and not medically able to
withstand a general anaesthetic (ASA
class III or higher), (3) immunodeficiency, (4) patients receiving radiation therapy, and (5) cases where
the surgical defect could be repaired,
primarily, without tension.
Study population
Fifteen patients were recruited for each
group, for a total of 30 patients. Patients
were triaged to each group depending on
the urgency for need of the surgical
excision and physical condition of subject so as not to compromise patient
care.
Demographics of Group 1 (grafted
with EVPOME) were five males, and ten
females. The ages of patients ranged
from 49 to 84 years with a mean age of
64.22.7 years. Lesions were located in
the tongue in 13 cases and alveolar gingiva in five cases (locations in three cases
of oral leukoplakia were multiple). The
lesions were histologically diagnosed as
squamous cell carcinoma in six cases (T
stage: T3=1, T2=1, T1=4), epithelial
dysplasia in eight and oral lichen planus
in one. Eight patients were non-smokers,
three had a positive smoking history but
did not smoke at the time of surgery and
four were current smokers in which one
patient was classified as a heavy smoker
(An index calculated by ‘number of currently smoked cigarettes per day’
‘years of smoking at the time of excision’
is 1000 or higher). In contrast, Group 2
(AlloDerm without seeded oral keratinocytes) contained ten males, and five
females. The ages of patients ranged
from 41 to 84 years with a mean age of
68.03.0 years. Lesions were located in
the tongue in 11 cases (T stage: T2=4,
T1=7) as well as the buccal mucosa,
floor of mouth, oropharyngeal mucosa
and alveolar gingiva. Histological diagnoses of the lesions were; 11 cases of
squamous cell carcinomas, four cases
of epithelial dysplasias with two of these
cases presenting with melanotic pigmentation. Eleven patients were nonsmokers and four were current smokers
with one patient classified as a heavy
smoker (Table 1).
Treatment protocol and follow-up
All oral lesions were resected with the
use of electrocautery. In all cases surgical margins of 10 mm around cancer or
5 mm around premalignant lesion were
done resulting in exposure of either the
underlying muscle or periosteum. Both
groups, EVPOME or AlloDerm, without epithelium, grafts were secured in
place with 4-0 black-silk sutures and
then stabilized by a gauze bolster pressure dressing (Fig. 2) or with a surgical
stent.
Patients were transnasally fed via a
nasogastric tube until postoperative day
7 and then placed on a soft diet. At day
6 postoperatively, the bolster or stent
was removed and at postoperative day 7
the sutures were removed. On average,
patients in both groups were discharged
2 weeks after surgery.
Outcome measures
At day 6, postoperatively, after removal
of the gauze bolster or surgical stent, the
most central portion of the surface of the
graft was scraped for cytological examination to assess for the presence of
Intraoral grafting of an ex vivo produced oral mucosa equivalent
Fig. 2. Clinical photographs showing a representative surgical procedure. (Top left) Outer solid
line is the incision line used to excise the lesion with a 5 mm surgical margin from the lesion that
is delineated by an inner solid line. (Top right) The lesion is excised and an open wound is
created. (Bottom left) Two circular pieces of EVPOME are applied onto the open wound and
sutured into place. (Bottom right) Gauze bolster is placed on the EVPOME.
Table 2. Postoperative outcomes of the EVPOME (Group 1) and AlloDerm alone (Group 2).
Group 1
EVPOME (15 pts)
Group 2
AlloDermalone (15 pts)
(15)
(15)
Adhesiveness
+ + + (15)
+ + (0)
+ + + (13)
+ + (2)
Epithelial coverage
+ + + (13)
+ + (2)
+ (0)
+ + + (0)
+ + (12)
+ (3)
Required days for epithelialization
27.41.2
46.02.8
Postoperative pain
Postoperative pain: + and units used for Visual Analog Scale (VAS) values ranging as
follows; = 0, + =1–24, + + =25–49, + + + =50–100.
Adhesive: + and units represent ‘Pull off strength’; =non-adherent, + =adherent but
easily removed, + + =adherent difficult to remove, + + + =adherent unable to remove.
Epithelial coverage: + and unit for % of epithelial coverage of grafted area at four weeks
post-grafting; =0–50%, + =51–75%, + + =76–99%, + + + =100%.
Required days for epithelialization: Values were expressed as the meanSEM. P value of
<0.05 indicates statistical significance.
grafted keratinocytes. Grafted sites of all
patients were evaluated by clinical observation and photographs every day until
discharge. Three variables were evaluated to assess patient and graft acceptance. First, postoperative pain was
assessed by a visual analog scale (VAS)
( =0, + =1–24, + + =25–49, + + +
=50–100). Secondly, ‘pull off strength’
was used to evaluate graft adhesiveness
to the underlying layer at the periphery
of the wound margin at day 7 postoperatively ( =non-adherent, + =adherent
but easily removed, + + =adherent difficult to remove, + + + =adherent unable
to remove). Third, the percent of epithelial coverage of the graft, clinically
evident at 4 weeks after transplantation,
was calculated by the formula of A-B/A
(%). ‘A’ was the wound area transplanted with EVPOME or AlloDerm
and ‘B’ was the area with exposed
AlloDerm (lack of epithelial coverage).
Areas of the grafts that had epithelial
coverage appeared red, while white or
opaque regions at the grafted site were
seen with AlloDerm which lacked an
epithelial layer ( =0–50%, + =51–
75%, + + =76–99%, + + + =100%). This
clinical assessment was subsequently
191
confirmed, by a postoperative histological biopsy. The ethical committee in
Niigata University Dental Hospital permitted only a single postoperative biopsy
to evaluate the grafts. Therefore, in lieu
of multiple biopsies from the same subject, we altered the timing of the one
biopsy in every ten cases. In fifteen cases,
a biopsy was performed at 4 weeks postoperatively, while the last five were done
at 2 weeks. The postoperative biopsy
was taken from the periphery of the
grafts in which both the EVPOME
and AlloDerm clinically appeared, to
possess an epithelial layer.
After discharge, all patients were
evaluated weekly for the first month,
bi-weekly for the next 2 months and then
monthly up to 12 months. At each postoperative visit, direct clinical observation and photographs were used to
evaluate and document wound healing.
The time period required to complete
epithelial coverage was determined by
the number of days between the day
of excision and the day full epithelial
coverage was achieved. Adverse events
were evaluated by daily reports during
hospitalization and at each visit after
discharge, as well as by a serum chemistry profile and a complete blood cell
count at day 7, 14, 28 days, 3, 6 months,
postoperatively.
Statistical analysis
Mann–Whitney U test was used to
determine the statistical significance
between the two groups: EVPOME and
AlloDerm. Values of P<0.05 were considered to be statistically significant.
Data was expressed as the meanSEM.
Results
There were a few demographic differences between, Group 1, EVPOME and
Group 2, AlloDerm. In Group 1, the
mean interval between punch biopsy and
excision, equal to days it took to fabricate the EVPOME prior to surgery, was
27.71.4 days whereas the mean interval between the first visit and excision
for Group 2, AlloDerm, was 13.71.5
days. This difference was statistically significant (P<0.01). This occurred because
our treatment protocol triaged patients
who had a clinical diagnosis of carcinoma, T1 or T2 into a group that had
the lesion excised as soon as possible
while the EVPOME cases were scheduled electively. Our triage treatment
policy resulted in a larger sample of
malignant lesions and males in Group 2,
192
Izumi et al.
Fig. 3. Cytological smear of grafts. A: Squamous cells seen on the smear, suggestive of the
presence of cultured keratinocytes (Papanicolaou staining). B: Numerous neutrophils within
mucinous exudates with no evidence of keratinocytes being present (Papanicolaou staining).
AlloDerm. In contrast, patient’s with a
positive smoking history, which plays a
role in etiology of malignant lesions
and can affect graft success rate, was
equal in both groups. The average surface area surgically covered by the
grafted EVPOME was 12.411.70 cm2,
while the mean area of coverage of
AlloDerm was 11.281.83 cm2. There
was no significant difference between the
two groups.
Postoperative course for both groups
of patients was uneventful. There were
no significant differences between both
groups in regard to postoperative pain
or adhesion of the graft to the underlying tissue while epithelial coverage
occurred more rapidly in Group 1 (Table
2). Patients who had lesions excised from
the tongue, in either group, experienced
occasional paraesthesia (dull sensation
and/or numbness). AlloDerm control
grafts experienced more tethering and
indurations of the tongue, secondary to
wound contraction, than EVPOME
grafts. Complete epithelial coverage was
achieved in the EVPOME grafts by
27.41.2 days while the AlloDerm
grafts required 46.02.8 days. The difference was statistically significant
(P<0.01).
At 6 days post-surgery, after removal
of pressure dressings, a cytological
sample was taken at the centre of the
graft, which revealed healthy single and
aggregates of epithelial cells on the surface of EVPOME, indicating the persistence of cultured oral keratinocytes on
the grafts (Fig. 3A). In contrast, the
cytological smear taken at the centre of
the AlloDerm, showed only numerous
neutrophils within a mucinous exudate
but no evidence of viable epithelial cells
(Fig. 3B). The surface of the transplanted EVPOME exhibited a dark red
hue that was found to correlate with
vascular ingrowth into the dermal
equivalent from the underlying host tissue (Fig. 4A). The AlloDerm grafts, in
contrast, were faintly red, indicating a
lesser degree of vascular infiltration (Fig.
4B). At the second week post-grafting,
after removal of the bolus or stent, host
granulation tissue was seen to extend
over the wound periphery in all patients
(Fig. 4A,B). In several patients a portion
of the surface of the AlloDerm, was
seen to have a ‘feather’ appearance during the second week after surgery (postoperative days 8 to 14). Histological
examination showed this to be necrotic
tissue infiltrated with bacteria (not
shown).
A biopsy taken at 2 weeks postgrafting, from an area that clinically
appeared epithelialized in both groups,
showed histologically the submucosal
layer to have an intense inflammatory
infiltrate among a bed of immature
granulation tissue with diluted, leaky
venules (Fig. 5A,B). The overlying epithelial layer in Group 1, EVPOME,
showed a well-ordered, thick spinous
layer, indicative of hyperplasia (Fig. 5C),
whereas that in Group 2, AlloDerm
alone, showed a more random irregular
regenerative pattern (Fig. 5D). At the 4
week biopsy, taken from an epithelialized area in both groups, Group 1,
EVPOME, showed a more mature, differentiated, overlying epithelium in contrast to, Group 2, AlloDerm, which
lacked the uniformity and epithelia regularity (Fig. 6A,B). An inflammatory
response was noted within the dermal
layer of both groups as documented
Intraoral grafting of an ex vivo produced oral mucosa equivalent
193
Discussion
Fig. 4. Typical appearances of EVPOME and AlloDerm grafts after transplantation. A:
EVPOME, Group 1 (the same case as shown in Fig. 2); Epithelialization starts from wound
edge. Note the full epithelial coverage obtained by 4 weeks post-grafting. Postoperative biopsy
is taken from the site shown by a white arrowhead. B: AlloDerm, Group 2; Note epithelial
coverage not completed at 4 weeks post-grafting. Postoperative biopsy is taken from the site
shown by an arrow.
by the plethora of blood vessels perpendicular to the overlying epithelium
(Fig. 6A,B). In Group 1, the dermal
component showed fewer numbers of
inflammatory cells and large venules
laden with ‘tall’ endothelial cells (Fig.
6C), and the presence of elongated
spindle-shaped fibroblasts among collagen bundles (Fig. 6E). Group 2, in contrast, showed evidence of a persistent
intense inflammatory response with
numerous giant cells and eosinophils
present within the dermis (Fig. 6D,F,
compared with Fig. 6C,E).
There were no clinical signs of a
foreign body response to either the
EVPOME or AlloDerm grafts with
healing eventually occurring uneventfully. Total serum chemistry profile after
grafting showed no systemic evidence of
an immunologic or systemic response to
the transplants.
Recently, tissue-engineered oral mucosa
substitutes have been applied onto open
wounds in the oral cavity1,4,11,14,18–20.
These oral mucosa substitutes can be
classified into three types17: (1) sheets
of cultured autologous keratinocytes4,11,18,19, (2) an artificial dermis
composed of collagen and/or glycosaminoglycans1,14, or (3) a composite
oral mucosa, containing both an epithelial and dermal layer20. These studies
have shown favorable outcomes using
the different types of grafts in reconstructive oral and maxillofacial surgery
but have several major deficiencies in
their experimental design and protocol;
the absence of a control group and a
small sample size, respectively. To our
knowledge, our investigation is the first
study evaluating the clinical application
of a composite human ex vivo produced
oral mucosa equivalent (EVPOME) with
a parallel control group, AlloDerm,
without epithelium with a sufficient
sample size to perform statistical
analysis.
The EVPOME utilized in our clinical
protocol is a composite or full-thickness
oral mucosa equivalent fabricated with
an epithelial and dermal layer. To date,
there has only been one other report on
the intraoral use of a bilayered cultured
oral mucosa. In that study the dermal
equivalent utilized was composed of a
Type I collagen gel repopulated with
fibroblasts20. A major disadvantage of
the use of collagen, intraorally, is its
fragility and early breakdown secondary
to the plethora of lytic enzymes present
within the oral cavity3. In addition, the
resurfacing of the oral cavity is more
difficult to accomplish than skin because
of a moist environment laden with
numerous microbial organisms, and
an undulating surface which can compromise graft stability. The use of
AlloDerm, as a dermal equivalent,
enhances the durability and compliance
of the EVPOME as well as improving
the handling characteristics assisting in
manufacture, intraoral placement and
stabilization of the graft at the surgical
site.
The use of an irradiated xenogeneic
3T3 mouse feeder layer, utilized in other
studies, has been shown to optimize the
in vitro culturing of keratinocytes, while
effecting stem cell maintenance resulting
in a longer life-span, and a more proliferative cell population16. The ability to
increase and maintain the number of
stem cells to sustain proliferation and
194
Izumi et al.
Fig. 5. Representative histologic findings of the postoperative biopsy at 2 weeks in EVPOME (A,C) and AlloDerm (B,D) grafts (haematoxylin
and eosin staining). A, B: Numerous eosinophils, lymphocytes, plasma cells, multinucleated giant cells and plumped fibroblasts are seen in the
deeper portion of the submucosal layer (original magnification 400). C: Epithelial layer demonstrates a thick spinous layer and elongated rete
ridges. Immature, highly vascular granulation tissue is present within the subjacent epithelial layer (original magnification 50). D: The basal
cell layer shows an increase of nucleus/cytoplasm ratio and disordered cellular arrangement. Note prominent inflammatory cell infiltration is
evident beneath epithelium (original magnification 75).
renewal of the keratinocyte population
would be beneficial in enhancing the
manufacture of the EVPOME. Unfortunately the optimization of keratinocyte
growth should not be at the cost of an
increase risk of cross contamination of
the cultured human keratinocytes with
xenogeneic material from the irradiated
3T3 feeder layer, especially in light that
the majority of oral and maxillofacial
surgical procedures are elective in nature
and the surgery can be timed to assure
the availability of an adequate population of autologous keratinocytes.
In our investigation, several observations indicated that the grafted
EVPOME had advantages over the use
of AlloDerm without epithelium. First,
was the early revascularization noted by
the increase in ‘redness’ of the EVPOME
graft; second, cytological evidence of the
presence of intact squamous cells within
the centre of the EVPOME graft at
postoperative day 6; third, a greater
reduction in dermal inflammatory
response, histologically, over time when
compared to the AlloDerm alone, and
fourth, the more rapid and mature epithelial coverage, observed clinically and
noted histologically, of the EVPOME
graft.
On postoperative day 6 after removal
of the pressure dressing, it was observed
that the grafted AlloDerm, without
epithelium, appeared to have an ‘ulcerative’ appearance secondary to the lack of
Intraoral grafting of an ex vivo produced oral mucosa equivalent
195
Fig. 6. Photomicrograph of histologic findings of the postoperative biopsy at 4 weeks in
EVPOME (A,C,E) and AlloDerm (B,D,F)
grafts (haematoxylin and eosin staining). A:
In the EVPOME a thick differentiated epithelial layer is present. A decreased inflammatory cell infiltration is present within the
dermal layer in which immature is being
replaced by fibrous connective tissue (original
magnification 50). B: There is disarray of
the epithelial layer of the AlloDerm. As well
an intense inflammatory response is still persistent. Numerous diluted blood vessels are
noted by their arrangement perpendicular to
the overlying epithelium (original magnification 60). C: A decrease in number of
inflammatory cells is seen within the
EVPOME. The thickness and diameter of the
blood vessels beneath the epithelium are
reduced (arrows) (original magnification
300). D: The AlloDerm alone shows the
continued presence of neutrophils, lymphocytes, macrophages and plumped fibroblasts
beneath
epithelium
(original
magnification 300). E: The EVPOME
shows few plumped fibroblasts and eosinophils within in the deeper portion of the
dermis (original magnification 300). F: In
the deeper portion of the AlloDerm, an
intense cellular infiltration containing numerous eosinophils (arrows) is observed (original
magnification 300).
196
Izumi et al.
an epithelial layer. In contrast, the
grafted EVPOME had a ‘slough off’
appearance of its superficial epithelial
layer as is usually seen in free gingival
grafts. It is known that this ‘sloughed
off’ tissue usually represents loss of the
more differentiated superficial stratified
cells of the transplant. Unfortunately, a
biopsy was not taken of the centre of the
EVPOME graft to confirm the presence
of an intact basal layer. It is, therefore,
assumed that basal cells of the epithelial
layer continued to remain attached to
the underlying dermal substrate. It is
most likely the presence of the persistent
epithelial basal cells of the EVPOME
grafts that were influential in allowing a
more rapid healing to occur. This, in
turn, resulted in a better colour rendition
of the EVPOME graft with the adjacent
mucosa as well as a marked reduction in
the underlying inflammatory response
within the dermal component.
The advantages noted with the use of
the EVPOME grafts may be the result
of the presence of an intact and mature
epithelial layer secreting keratinocytederived cytokines, such as vascular
endothelial growth factor (VEGF) that
effect dermal vascularity. We have
observed that human oral keratinoctyes
can naturally secrete high endogenous
levels of VEGF in culture (data not
shown). The release of VEGF and
associated cytokines may have moderated the inflammatory response,
enhanced cell growth, neoangiogenesis,
and wound healing while minimizing
graft contracture2,5,13. According to
Y et al.21, the initial 2–3 days after
transplantation are critical to graft survival and is predicated on vascular
ingrowth into the transplants via the
process of inosculation in association
with neoangiogenesis. The presence of
numerous intact acellular blood vessel
channels, within the dermal layer, that
are maintained within the architecture of
the AlloDerm after preparation may
also have assisted in the early revascularization of the dermal equivalent in
both groups.
An intact epithelium has been noted
to create a barrier effect of the overlying dermis protecting it from bacterial
invasion6. In addition, the intact keratinocyte layer on the EVPOME could
have been a source of other released
growth factors, such as transforming
growth factor alpha (TGF) and epidermal growth factor (EGF) that could
influence host epithelial cells proliferation and migration from the margin of
the wounds thus enhancing epithelial
coverage resulting in less of an inflammatory response within the dermal component12. The presence of a persistent
epithelium on the EVPOME transplants would also potentially make them
useful as a device for grafting of genetically modified keratinocytes that may
be beneficial for various therapeutic
applications15.
There were no systemic complications
seen in either Group 1 or 2 after grafting. Postoperative pain was minimal in
both groups of patients with evidence of
slight neurosensory deficits observed in
some of the cases involving reconstruction of the tongue. Kangesu10 noted that
nerve regeneration, into a grafted skin
equivalent, composed of de-epidermized
dermis and cultured keratinocytes, followed re-vascularization. Thus, since the
tongue contains a rich nerve plexus
within its musculature longer follow up
may see a resolution to this adverse
outcome.
In our study, it was noted that the
AlloDerm grafts, without epithelium,
resulted in a more indurated and contracted wound than seen with the
EVPOME grafts, post transplantation.
Severe wound contraction, which is seen
in healing by second intention, can result
in post-grafting morbidity, leading to
functional disturbances in speech by
restriction of the mobility of the tongue.
Garner demonstrated that early epidermal coverage prevented excessive collagen synthesis within the underlying
dermal fibroblasts and can minimize
wound contracture7. The smaller degree
of wound contracture seen with the
EVPOME grafts may be the result of the
establishment of an intact and mature
epithelial layer influencing underlying
collagen synthesis within the dermal
component, AlloDerm. It also appears
that the persistence of the cultured
autologous keratinocytes on the
EVPOME played a key role in assisting
in its integration into the underlying host
tissue. In addition the inflammatory
cellular infiltrate within the dermis
decreased more dramatically from week
2 through 4, postoperatively, in the
EVPOME, in contrast to the persistent
inflammatory infiltrate seen in Group 2,
AlloDerm without an epithelial layer.
The evidence of less induration at the
wound site in the EVPOME graft may
be related to a more physiologic repair
of the underlying dermal layer secondary
to the presence of an intact epithelial
layer that has the capability to secrete
pro-inflammatory cytokines and growth
factors resulting in a more moderate and
shortened inflammatory phase of wound
repair.
Retrospective evaluation of our
clinical study with grafted EVPOMEs,
revealed several design and logistical
deficiencies:
1. Only one biopsy was allowed and it
was not taken at the same time
period.
2. Biopsies were taken from the periphery of the graft (from areas that
‘appeared’ to have an epithelial layer)
and not from the graft centre. This
did not allow us to assess the absence
or presence of a basal epithelial
layer on either type of graft at a site
that would be less influenced, the
centre, by migration of cells from
the periphery of the reconstructed
wound.
3. The use of specific stains may have
added additional information.
4. A blinded evaluator did not clinically
assess the grafts and would have
added more objectivity to the clinical
evaluation.
5. A thinner dermal equivalent may
have resulted in a faster vascular
ingrowth but may also have impaired
the handling characteristics (curling
up of the margins during manufacture). This issue will have to be
evaluated in future studies.
6. The majority of the surgical sites were
the tongue, a highly mobile organ. A
non-mobile bony recipient site, such
as a maxillary or mandibular ridge,
may have been more predictable
in stabilization of the grafts thus
enhancing re-vascularization and
maintaining the epithelial layer.
7. Elimination of the use of pituitary
extract in the manufacturing process
of the EVPOME to create a more
defined and ‘clean’ system. This point
has, in fact, been accomplished in our
laboratory and will be incorporated
into future investigations.
8. We are planning, in the future, a
randomized, controlled multi-centre
study using patients with nonmalignant lesions that would allow
more similarity between the groups
being evaluated.
In summary, it appears that the
EVPOME graft may be a more acceptable oral mucosa substitute for human
intraoral grafting procedures resulting
in a more favorable wound healing
response than the AlloDerm graft
without an epithelial layer. The advantage of the EVPOME over the
Intraoral grafting of an ex vivo produced oral mucosa equivalent
AlloDerm may have been due to the
persistence of a transplanted epithelial
basal cell layer resulting in the development of a more rapid and mature epithelium. The persisted basal layer of
grafted keratinocytes and/or the initial
presence of an intact epithelial layer,
developed in vitro, at the time of
grafting of the EVPOME, may have
given it a decided advantage in eventual
repair and healing of the surgical
wound by the release of cytokines and
growth factors that are known to be
secreted by keratinoctyes. Additional
studies will give us more insight into
the potential benefits of the use of a
tissue engineered human oral mucosal
equivalent as an aid in surgical reconstruction and as a vehicle for use in
gene therapy.
Acknowledgments. We would like to
thank Dr Satoshi Maruyama and
Professor Takashi Saku for their help in
evaluating the histology of the biopsies
and Masaaki Hoshino for excellent technical assistance. The authors thank
Professors Ritsuo Takagi and Chikara
Saito for their helpful suggestions. We
also thank the Oral & Maxillofacial
Surgeons in Niigata University for their
cordial patient care and cooperation
with this study.
This work was supported by Grant-inAid for Scientific Research (No.
12771216) from the Ministry of Education, Science and Culture, Japan,
Grant for the Promotion of Niigata
University Research Projects, and Grant
from Kato Memorial Bioscience
Foundation (KI) and US PHS Grant
NIDCR/NIH R01 DE 13417 (SEF).
References
1. B K, M K, I T. The
use of a new bilayer artificial dermis for
vestibular extension. Br J Oral Maxillofac
Surg 1998: 36: 457–459.
2. B LF, Y K-T, B B, Y TK,
S DR, D HF, V 
W L. Expression of vascular permeability factor (vascular endothelial
growth factor) by epidermal keratinocytes during wound healing. J Exp Med
1992: 176: 1375–1379.
3. C KH, A HT, P KC, C
JH, K SW, S MW, K KH,
C PH, E HC, Y JI.
Reconstruction of human hard-palate
mucosal epithelium on de-epidermized
dermis. J Dermatol Sci 2000: 22: 117–124.
4. D L M, A E, M M,
C R, M PE, C
A, F AT. Evidence that human oral
epithelium reconstituted in vitro and
transplanted onto patients with defects in
the oral mucosa retains properties of the
original donor site. Transplantation 1990:
50: 454–459.
5. D M, Y K-T, N JA,
V  W L, B LF, B B,
E BM, L S, D
HF. Keratinocyte-derived vascular permeability factor (vascular endothelial
growth factor) is a potent mitogen for
dermal microvascular endothelial cells. J
Invest Dermatol 1995: 105: 44–50.
6. F V, M D, A O,
A M, M F, A
M, J J, S M, HY J. Rapid healing of venous ulcers
and lack of clinical rejection with an
allogeneic cultured human skin equivalent. Arch Dermatol 1998: 134: 293–300.
7. G WL. Epidermal regulation of
dermal fibroblast activity. Plast Reconstr
Surg 1998: 102: 135–139.
8. I K, F SE, T H,
M CL. Evaluation of transplanted
tissue-engineered oral mucosa equivalent
to SCID mice. Tissue Engineering Feb
2003: in press.
9. I K, T H, M CL,
F SE. Development and characterization of a tissue-engineered human
oral mucosa equivalent produced in a
serum-free culture system. J Dent Res
2000: 79: 798–805.
10. K T, M S, T G, G
X-H, N HA, P JM, G
CJ, L IM. Nerve and blood vessel
growth in response to grafted dermis and
cultured keratinocytes. Plast Reconstr
Surg 1998: 101: 1029–1038.
11. L G, S R. Tissueengineered mucosa graft for reconstruction of the intraoral lining after freeing of
the tongue: a clinical and immunohistologic study. J Oral Maxillofac Surg 2001:
59: 169–177.
12. M P. Wound healing-aiming for
perfect skin regeneration. Science 1997:
276: 75–81.
13. M S, N H, S R,
G C, L I. Transplantation of
keratinocytes in the treatment of wounds.
Am J Surg 1995: 170: 75–83.
197
14. O S, M N, H S,
K R, F K. A newly developed
collagen/silicone bilayer membrane as a
mucosal substitute: a preliminary report.
Br J Oral Maxillofac Surg 1997: 35:
85–91.
15. O’T G, M D, B
MF, L R, P M. A review of
therapeutic angiogenesis and consideration of its potential applications to plastic
and reconstructive surgery. Br J Plast
Surg 2001: 54: 1–7.
16. P G, R R, S G,
B S, G L, Z G,
M G, D L M. The control of
epidermal stem cells (holoclones) in the
treatment of massive full-thickness burns
with autologous keratinocytes cultured
on fibrin. Transplantation 1999: 68: 868–
879.
17. P TJ. New skin for old. Arch
Dermatol 1998: 134: 344–349.
18. R
GM,
T
AM,
S J, B EH, W MJH,
V A. Use of cultured mucosal
grafts to cover defects caused by vestibuloplasty: An in vitro study. J Oral
Maxillofac Surg 1995: 53: 872–878.
19. T C-Y, U M, H K, H K,
H Y, S Y, T K,
T S. Clinical results of cultured epithelial cell grafting in the oral and maxillofacial region. J Cranio-Maxillofac Surg
1997: 25: 4–8.
20. U M, E K, K T. In vitro
fabrication of bioartificial mucosa for
reconstruction of oral mucosa: basic
research and clinical application. Ann
Plast Surg 1991: 27: 540–549.
21. Y DM, G KM, W HG.
Species-specific in situ hybridization with
fluorochrome-labeled DNA probes to
study vascularization of human skin
grafts on athymic mice. J Burn Care
Rehabil 1996: 17: 305–310.
Address:
Kenji Izumi, DDS, PhD
Department of Oral and Maxillofacial
Surgery
University of Michigan Medical Center,
UH-B1-204
1500 E. Medical Center Dr.
Ann Arbor
MI 48109-0018
USA
Tel: +1-734-615-8708
Fax: +1-734-936-5941
E-mail: kennie@umich.edu

Similar documents

Evaluation of Transplanted Tissue

Evaluation of Transplanted Tissue Transplantation of ex vivo-produced oral mucosa equivalent into SCID mice The University of Michigan Committee on Use and Care of Animals approved all animal studies. The grafts were transplanted i...

More information

A New in Vitro Model of Cancer Invasion Using AlloDerm®, a

A New in Vitro Model of Cancer Invasion Using AlloDerm®, a Normal epithelial cells obtained from the oral mucosa were cultured under a high calcium concentration to enhance keratinocyte differentiation. The equivalents were raised to an air-liquid interfac...

More information

PDF file

PDF file of oral mucosa, while the mucosa is quantitatively limited as a donor source. Moreover, both skin and mucosal grafting leads to tissue defects at the donor site. Advances in tissue engineering tech...

More information